心内膜切片检查市场 - 全球产业规模、份额、趋势、机会、预测：按产品、高级零件、最终用途、地区和竞争对手划分，2021-2031 年

全球心肌切片检查市场预计将从 2025 年的 3.7168 亿美元成长到 2031 年的 5.4941 亿美元，复合年增长率为 6.73%。

心肌切片切片检查是一种侵入性诊断方法，它使用切片检查钳取少量心肌组织样本，是识别移植患者同种异体移植排斥反应和诊断某些心肌病的重要技术。市场成长的主要驱动因素是全球心臟衰竭患者数量的增加以及心臟移植手术数量的上升，这些手术需要频繁的术后后续观察以确保移植器官的存活。此外，导管引导系统的不断进步和切片检查钳安全性的提高也持续支持着此诊断方法在临床上的应用。

根据国际心肺移植协会的数据，2024年全球共进行了超过6,000例心臟移植手术。如此庞大的手术量直接推动了对切片检查器械的需求，因为患者在移植后的关键第一年通常需要多次后续观察切片检查。儘管需求稳定，但由于该技术的侵入性，市场仍面临许多挑战。诸如心臟穿孔等併发症的风险促使人们更加关注磁振造影（MRI）等非侵入性诊断方法的研发。

市场驱动因素

全球心臟移植手术数量的不断增长是推动市场扩张的主要动力。这些手术需要严格的术后监测，以识别移植排斥反应。心肌内切片检查是目前公认的临床标准方法，在每次移植手术后，患者復原过程中都会反覆使用该仪器。根据美国器官移植网络（UNOS）2024年1月的数据，2023年美国共进行了4,519例心臟移植手术。如此高的数字凸显了对监测的高需求，而这一趋势在全球范围内普遍存在。例如，英国国家医疗服务体系（NHS）血液和移植机构的一份报告显示，截至2024年底，英国心臟移植等待名单上有328名患者，这凸显了心臟科需要持续保持强大的切片检查能力，以满足未来患者的需求。

同时，随着心肌炎和心肌病发病率的上升，精确的组织学特征分析对于制定治疗策略至关重要。当非侵入性影像学检查无法确定心臟衰竭的病因时，医生不得不依赖组织取样来鑑别诸如心臟类淀粉沉积症和鉅细胞性心肌炎等复杂疾病。根据美国心臟协会2024年1月报告，目前美国约有670万成年人患有心臟衰竭。如此沉重的疾病负担凸显了诊断性切片检查的持续必要性，医生也越来越依赖组织学分析来确定不明原因心臟功能障碍患者的最佳治疗方案。

市场挑战

全球心肌切片检查市场的主要障碍在于其侵入性，严重阻碍了其广泛应用。采集心肌组织本身就存在严重併发症的风险，包括心律不整、瓣膜损伤和心臟穿孔。这些安全隐患常常导致临床医师在建议进行临床后续观察的情况下，也不愿意频繁进行切片检查。因此，医疗机构越来越重视非侵入性诊断方法，例如磁振造影（MRI）。 MRI 是一种更安全的方法，可以在不进行组织采集的情况下识别病变，避免了相关併发症。

这些营运限制直接限制了市场利用心血管疾病日益增长的趋势的能力。根据美国心臟衰竭协会统计，到2024年，美国将有约670万成年人患有心臟衰竭。儘管如此巨大的疾病负担为诊断监测提供了广泛的潜在市场，但切片检查相关的风险使得这种方法难以成为日益增长的患者群体的常规标准治疗手段。因此，该市场目前仅限于小规模部分病情严重的患者，在这些患者中，侵入性风险被认为是可接受的，从而限制了其整体成长潜力。

市场趋势

基因组和分子层面的排斥反应监测正在从根本上改变全球心肌切片检查市场，将临床标准从固定的检测方案转变为标靶监测。医疗服务提供者不再让心臟移植患者频繁接受侵入性检查，而是越来越多地采用非侵入性液态生物检体来筛检移植损伤，并将组织取样限制在分子标记升高的患者中。这种通讯协定的改变显着减少了不必要的手术次数，同时密切监测移植器官的健康状况。例如，CareDx公司在2024年5月发布的一份关于SHORE註册研究的新闻稿指出，与传统的切片检查主导的通讯协定相比，采用多方面分子监测后，心臟科医生在移植两年后进行的切片检查次数减少了40%。

同时，人工智慧增强型数位病理工作流程的引入正在革新术后分析阶段，消除切片检查解读中的一个主要瓶颈：组织学变异性。透过从人工显微镜检查转向数位化切片扫描与深度学习演算法的结合，检查室可以自动测量淋巴细胞浸润等排斥标誌物，从而确保不同心臟中心之间诊断结果的一致性。这种技术融合提升了每次切片检查的临床价值，并透过更优的数据收集验证了侵入性操作的有效性。根据《CAP TODAY》2024年12月的一篇报导报道，临床检查室采用数位病理解决方案的比例已达到约10%，这表明自动化诊断正显着向高精度组织分析转型。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球心内膜切片检查市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品分解（镊子、配件）
  • 笔尖形状（超弯、直尖、预弯、其他）
  • 按用途（医院、门诊手术中心、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美心内膜切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲心内膜切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区心内膜切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲心内膜切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲心内膜切片检查市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球心内膜切片检查市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Argon Medical Devices Inc.
• Cordis
• Mermaid Medical Group
• Terumo Corp.
• Scholten Surgical Instruments, Inc.
• Changzhou Toolmed Medical Instrument Co., Ltd.
• Fehling Surgical Instruments Inc.
• SternMed GmbH
• Olympus Corporation of the Americas
• Heart Medical Europe BV

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Endomyocardial Biopsy Market is projected to expand from USD 371.68 Million in 2025 to USD 549.41 Million by 2031, growing at a CAGR of 6.73%. As an invasive diagnostic procedure, endomyocardial biopsy involves using a bioptome to extract small samples of heart muscle tissue, serving as a critical method for identifying allograft rejection in transplant patients and diagnosing specific cardiomyopathies. The market is primarily fueled by the increasing global rates of heart failure and the associated rise in heart transplantation surgeries, which require frequent post-operative monitoring to ensure graft viability. Additionally, ongoing advancements in catheter guidance systems and the safety of biopsy forceps continue to support the utilization of this diagnostic standard within clinical environments.

According to the International Society for Heart and Lung Transplantation, over 6,000 heart transplant operations were conducted globally in 2024. This volume of procedures directly sustains the demand for biopsy instruments, as patients typically require multiple surveillance biopsies during the crucial first year following transplantation. Despite this consistent demand, the market encounters significant obstacles due to the invasive nature of the technique; the potential risks of complications, such as cardiac perforation, are driving interest in and development of non-invasive diagnostic options like cardiac magnetic resonance imaging.

Market Driver

The growing number of heart transplant procedures worldwide serves as the main engine for market expansion, as these surgeries require strict post-operative monitoring to identify allograft rejection. Because endomyocardial biopsy is the established clinical standard for this purpose, every transplant generates a recurring necessity for device usage throughout a patient's recovery process. Data from the United Network for Organ Sharing in January 2024 highlighted that healthcare providers completed 4,519 heart transplants in the United States in 2023. This high volume reinforces the demand for surveillance, a pattern observed globally; for instance, NHS Blood and Transplant reported that the active heart transplant waiting list in the United Kingdom included 328 patients by the end of 2024, signaling continued pressure on cardiac units to maintain strong biopsy capabilities for future patients.

At the same time, the rising prevalence of myocarditis and cardiomyopathies necessitates precise tissue characterization to direct treatment plans. When non-invasive imaging fails to clarify the cause of heart failure, doctors depend on tissue extraction to distinguish between complex disorders such as cardiac amyloidosis and giant cell myocarditis. As reported by the American Heart Association in January 2024, roughly 6.7 million adults in the United States currently suffer from heart failure. This significant burden of disease guarantees a continuous need for diagnostic biopsies, as physicians increasingly emphasize histological analysis to identify the best management approaches for patients with unexplained cardiac dysfunction.

Market Challenge

The central obstacle hindering the Global Endomyocardial Biopsy Market is the invasive character of the procedure, which presents a significant hurdle to widespread usage. Extracting heart muscle tissue involves intrinsic risks of serious complications, such as arrhythmias, valve damage, and cardiac perforation. These safety issues discourage clinicians from performing biopsies frequently, even in cases where longitudinal tracking is clinically advised. As a result, medical providers are progressively favoring non-invasive diagnostic substitutes, including cardiac magnetic resonance imaging, which provide safer methods for identifying pathologies without the morbidity risks linked to physical tissue removal.

This operational constraint directly limits the market's capacity to leverage the rising prevalence of cardiovascular diseases. According to the Heart Failure Society of America, approximately 6.7 million adults in the United States were living with heart failure in 2024. Although this extensive disease burden offers a vast addressable market for diagnostic monitoring, the dangers associated with biopsies prevent the technique from becoming the routine standard of care for this growing patient population. Consequently, the market is confined to a smaller segment of critical cases where the invasive risks are considered acceptable, thereby restricting overall growth potential.

Market Trends

The move toward genomic and molecular-based rejection monitoring is fundamentally transforming the Global Endomyocardial Biopsy Market by shifting the clinical standard from fixed procedural timetables to targeted surveillance. Rather than subjecting heart transplant patients to frequent invasive checks, healthcare providers are increasingly using non-invasive liquid biopsies to screen for graft injury, limiting tissue extraction to patients who exhibit elevated molecular markers. This change in protocol significantly lowers the total number of unnecessary procedures while ensuring strict monitoring of graft health; for example, a May 2024 press release from CareDx, Inc. regarding the SHORE registry noted that cardiologists performed 40% fewer biopsies in the second post-transplant year when using multimodal molecular surveillance compared to traditional biopsy-led protocols.

Concurrently, the adoption of AI-enhanced digital pathology workflows is modernizing the post-procedural analysis stage, resolving the major bottleneck of histological variability in interpreting biopsies. By moving from manual microscopy to digitized slide scanning combined with deep learning algorithms, labs can automate the measurement of rejection markers like lymphocyte infiltration, ensuring better diagnostic consistency across various cardiac centers. This technological convergence improves the clinical value of every biopsy, justifying the invasive nature of the procedure through superior data retrieval. According to an article in CAP TODAY from December 2024, the adoption rate of digital pathology solutions in clinical labs has reached roughly 10%, signaling a critical shift toward automated diagnostics that enable high-precision tissue analysis.

Key Market Players

• Argon Medical Devices Inc.
• Cordis
• Mermaid Medical Group
• Terumo Corp.
• Scholten Surgical Instruments, Inc.
• Changzhou Toolmed Medical Instrument Co., Ltd.
• Fehling Surgical Instruments Inc.
• SternMed GmbH
• Olympus Corporation of the Americas
• Heart Medical Europe BV

Report Scope

In this report, the Global Endomyocardial Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endomyocardial Biopsy Market, By Product

• Forceps
• Accessories

Endomyocardial Biopsy Market, By Tip

• Maxi-curved
• Straight
• Pre-curved
• Others

Endomyocardial Biopsy Market, By End-Use

• Hospitals
• Ambulatory Surgical Centers
• Others

Endomyocardial Biopsy Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endomyocardial Biopsy Market.

Available Customizations:

Global Endomyocardial Biopsy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endomyocardial Biopsy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Forceps, Accessories)
  • 5.2.2. By Tip (Maxi-curved, Straight, Pre-curved, Others)
  • 5.2.3. By End-Use (Hospitals, Ambulatory Surgical Centers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Endomyocardial Biopsy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Tip
  • 6.2.3. By End-Use
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Endomyocardial Biopsy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Tip
      • 6.3.1.2.3. By End-Use
  • 6.3.2. Canada Endomyocardial Biopsy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Tip
      • 6.3.2.2.3. By End-Use
  • 6.3.3. Mexico Endomyocardial Biopsy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Tip
      • 6.3.3.2.3. By End-Use

7. Europe Endomyocardial Biopsy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Tip
  • 7.2.3. By End-Use
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Endomyocardial Biopsy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Tip
      • 7.3.1.2.3. By End-Use
  • 7.3.2. France Endomyocardial Biopsy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Tip
      • 7.3.2.2.3. By End-Use
  • 7.3.3. United Kingdom Endomyocardial Biopsy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Tip
      • 7.3.3.2.3. By End-Use
  • 7.3.4. Italy Endomyocardial Biopsy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Tip
      • 7.3.4.2.3. By End-Use
  • 7.3.5. Spain Endomyocardial Biopsy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Tip
      • 7.3.5.2.3. By End-Use

8. Asia Pacific Endomyocardial Biopsy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Tip
  • 8.2.3. By End-Use
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Endomyocardial Biopsy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Tip
      • 8.3.1.2.3. By End-Use
  • 8.3.2. India Endomyocardial Biopsy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Tip
      • 8.3.2.2.3. By End-Use
  • 8.3.3. Japan Endomyocardial Biopsy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Tip
      • 8.3.3.2.3. By End-Use
  • 8.3.4. South Korea Endomyocardial Biopsy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Tip
      • 8.3.4.2.3. By End-Use
  • 8.3.5. Australia Endomyocardial Biopsy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Tip
      • 8.3.5.2.3. By End-Use

9. Middle East & Africa Endomyocardial Biopsy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Tip
  • 9.2.3. By End-Use
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Endomyocardial Biopsy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Tip
      • 9.3.1.2.3. By End-Use
  • 9.3.2. UAE Endomyocardial Biopsy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Tip
      • 9.3.2.2.3. By End-Use
  • 9.3.3. South Africa Endomyocardial Biopsy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Tip
      • 9.3.3.2.3. By End-Use

10. South America Endomyocardial Biopsy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Tip
  • 10.2.3. By End-Use
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Endomyocardial Biopsy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Tip
      • 10.3.1.2.3. By End-Use
  • 10.3.2. Colombia Endomyocardial Biopsy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Tip
      • 10.3.2.2.3. By End-Use
  • 10.3.3. Argentina Endomyocardial Biopsy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Tip
      • 10.3.3.2.3. By End-Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Endomyocardial Biopsy Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Argon Medical Devices Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Cordis
• 15.3. Mermaid Medical Group
• 15.4. Terumo Corp.
• 15.5. Scholten Surgical Instruments, Inc.
• 15.6. Changzhou Toolmed Medical Instrument Co., Ltd.
• 15.7. Fehling Surgical Instruments Inc.
• 15.8. SternMed GmbH
• 15.9. Olympus Corporation of the Americas
• 15.10. Heart Medical Europe BV

16. Strategic Recommendations

17. About Us & Disclaimer